$7.21
7.61% yesterday
Nasdaq, Sep 27, 10:02 pm CET
ISIN
CA98400H1029
Symbol
XBIT
Sector
Industry

XBiotech, Inc. Stock price

$7.21
+0.71 10.92% 1M
-0.78 9.76% 6M
+3.21 80.25% YTD
+3.19 79.35% 1Y
-7.68 51.58% 3Y
-1.88 20.72% 5Y
-13.34 64.91% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.51 7.61%
ISIN
CA98400H1029
Symbol
XBIT
Sector
Industry

Key metrics

Market capitalization $204.10m
Enterprise Value $25.57m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.04
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-42.93m
Free Cash Flow (TTM) Free Cash Flow $-24.53m
Cash position $188.53m
EPS (TTM) EPS $-1.15
Short interest 4.78%
Show more

Is XBiotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

XBiotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast XBiotech, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast XBiotech, Inc.:

Hold
100%

Financial data from XBiotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.73 1.73
24% 24%
-
-1.73 -1.73
458% 458%
-
- Selling and Administrative Expenses 1.30 1.30
69% 69%
-
- Research and Development Expense 38 38
20% 20%
-
-41 -41
25% 25%
-
- Depreciation and Amortization 1.73 1.73
16% 16%
-
EBIT (Operating Income) EBIT -43 -43
23% 23%
-
Net Profit -35 -35
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about XBiotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

XBiotech, Inc. Stock News

Neutral
GlobeNewsWire
3 months ago
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy
Neutral
Seeking Alpha
4 months ago
XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke. Other studies being deployed are Natrunix for the treatment of patients with pancreatic cancer and rheumatoid arthritis. While other biologics have targeted IL-1, none have been established to specifically target IL-1a.
Neutral
GlobeNewsWire
9 months ago
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024.
More XBiotech, Inc. News

Company Profile

XBiotech, Inc. is a biopharmaceutical company. The firm engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Head office Canada
CEO John Simard
Employees 82
Founded 2005
Website www.xbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today